Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain

Journal of Clinical Investigation

Volumn 119, Issue 3, 2009, Pages 504-511

  Gao, Cunji ^a   Boylan, Brian ^a   Bougie, Dan ^a   Gill, Joan C ^b   Birenbaum, Jessica ^a   Newman, Debra K ^a,b   Aster, Richard H ^a,b   Newman, Peter J ^a,b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTIBODY; BETA3 INTEGRIN; EPTIFIBATIDE; FC RECEPTOR IIA; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE SYK; ANTITHROMBOCYTIC AGENT; FC RECEPTOR; HEPARIN; PEPTIDE;

AGED; ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; GLANZMANN DISEASE; HUMAN; HUMAN CELL; MALE; POSTOPERATIVE THROMBOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; THROMBOSIS; ANTIBODY PRODUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

AGED; ANTIBODIES; ANTIBODY FORMATION; BLOOD PLATELETS; CORONARY STENOSIS; HEPARIN; HUMANS; IMMUNOGLOBULIN G; INTEGRIN BETA3; MALE; PEPTIDES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RECEPTORS, IGG; SIGNAL TRANSDUCTION; STENTS; THROMBASTHENIA; THROMBOCYTOPENIA; THROMBOSIS;

EID: 65649101237     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36745     Document Type: Article

References (82)

1. Shattil, S.J., and Newman, P.J. 2004. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 104:1606-1615.
2. Fitzgerald, D.J., Roy, L., Catella, F., and Fitzgerald, G.A. 1986. Platelet activation in unstable coronary disease. N. Engl. J. Med. 315:983-989.
3. American Heart Association. 2008. Heart disease and stroke statistics - 2008 update. American Heart Association. Dallas, Texas, USA. http://www. americanheart.org/presenter.jhtml?identifier= 3000090.
4. Lefkovits, J., Plow, E.F., and Topol, E.J. 1995. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 332:1553-1559.
5. Vorchheimer, D.A., Badimon, J.J., and Fuster, V. 1999. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 281:1407-1414.
6. Tcheng, J.E., and O'Shea, J.C. 1999. Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa. Expert Opin. Investig. Drugs. 8:1893-1905.
7. Scarborough, R.M. 1999. Development of eptifibatide. Am. Heart J. 138:1093-1104.
8. Tcheng, J.E. 1997. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am. J. Cardiol. 80:21B-28B.
9. [No authors listed.] 1998. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. 339:436-443.
10. Esprit Investigators. 2000. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 356:2037-2044.
11. ADVANCE MI Investigators. 2005. Facilitated percutaneous coronary intervention for acute STsegment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am. Heart J. 150:116-122.
12. McClure, M.W., et al. 1999. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/ IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation. 99:2892-2900.
13. Hongo, R.H., and Brent, B.N. 2001. Association of eptifibatide and acute profound thrombocytopenia. Am. J. Cardiol. 88:428-431.
14. Tanaka, K.A., Vega, J.D., Kelly, A.B., Hanson, S.R., and Levy, J.H. 2003. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J. Thromb. Haemost. 1:392-394.
15. Suleiman, M., et al. 2003. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J. Invasive Cardiol. 15:319-323.
16. Fahdi, I.E., et al. 2004. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 93:453-455.
17. Aster, R.H. 2005. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 127:53S-59S.
18. Du, X.P., et al. 1991. Ligands "activate" integrin αIIbβ3 (platelet GPIIb- IIIa). Cell. 65:409-416.
19. Kouns, W.C., et al. 1992. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 80:2539-2547.
20. Peter, K., et al. 1998. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood. 92:3240-3249.
21. Cox, D., et al. 2000. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J. Am. Coll. Cardiol. 36:1514-1519.
22. Hantgan, R.R., Stahle, M.C., Connor, J.H., Connor, R.F., and Mousa, S.A. 2007. αIIbβ3 priming and clustering by orally active and intravenous integrin antagonists. J. Thromb. Haemost. 5:542-550.
23. Bougie, D.W., et al. 2002. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligandoccupied GPIIb/IIIa. Blood. 100:2071-2076.
24. Epelman, S., Nair, D., Downey, R., Militello, M., and Askari, A.T. 2006. Eptifibatide-induced thrombocytopenia and thrombosis. J. Thromb. Thrombolysis. 22:151-154.
25. Gulino, D., Ryckewaert, J.J., Andrieux, A., Rabiet, M.J., and Marguerie, G. 1990. Identification of a monoclonal antibody against platelet GPIIb that interacts with a calcium-binding site and induces aggregation. J. Biol. Chem. 265:9575-9581.
26. Kouns, W.C., Wall, C.D., White, M.M., Fox, C.F., and Jennings, L.K. 1990. A conformation-dependent epitope of human platelet glycoprotein IIIa. J. Biol. Chem. 265:20594-20601.
27. Frelinger, A.L., Du, X.P., Plow, E.F., and Ginsberg, M.H. 1991. Monoclonal antibodies to ligand-occupied conformers of integrin αIIbβ3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J. Biol. Chem. 266:17106-17111.
28. Horsewood, P., Hayward, C.P.M., Warkentin, T.E., and Kelton, J.G. 1991. Investigation of the mechanism of monoclonal antibody-induced platelet activation. Blood. 78:1019-1026.
29. Slupsky, J.R., Cawley, J.C., Griffith, L.S., Shaw, A.R., and Zuzel, M. 1992. Role of FcγRII in platelet activation by monoclonal antibodies. J. Immunol. 148:3189-3194.
30. Rosenfeld, S.I., et al. 1985. Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes. J. Clin. Invest. 76:2317-2322.
31. Hibbs, M.L., Bonadonna, L., Scott, B.M., McKenzie, I.F., and Hogarth, P.M. 1988. Molecular cloning of a human immunoglobulin G Fc receptor. Proc. Natl. Acad. Sci. U. S. A. 85:2240-2244.
32. Brooks, D.G., Qiu, W.Q., Luster, A.D., and Ravetch, J.V. 1989. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J. Exp. Med. 170:1369-1385.
33. Van den Herik-Oudijk, I.E., et al. 1995. Identification of signaling motifs within human FcγRIIa and FcγRIIb isoforms. Blood. 85:2202-2211.
34. Yanaga, F., et al. 1995. Syk interacts with tyrosinephosphorylated proteins in human platelets activated by collagen and cross-linking of the FcγIIA receptor. Biochem. J. 311:471-478.
35. Anderson, C.L., Chacko, G.W., Osborne, J.M., and Brandt, J.T. 1995. The Fc receptor for immunoglobulin G (FcγRII) on human platelets. Semin. Thromb. Hemost. 21:1-9.
36. Huang, M.M., et al. 1992. Activation of FcγRII induces tyrosine phosphorylation of multiple proteins including FcγRII. J. Biol. Chem. 267:5467-5473.
37. Chacko, G.W., et al. 1994. Clustering of the platelet Fc gamma receptor induces noncovalent association with the tyrosine kinase p72syk. J. Biol. Chem. 269:32435-32440.
38. Saci, A., Pain, S., Rendu, F., and Bachelot-Loza, C. 1999. Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves p120(Cbl). J. Biol. Chem. 274:1898-1904.
39. Bodin, S., Viala, C., Ragab, A., and Payrastre, B. 2003. A critical role of lipid rafts in the organization of a key FcγRIIa-mediated signaling pathway in human platelets. Thromb. Haemost. 89:318-330.
40. Ragab, A., et al. 2003. The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon FcγRIIa crosslinking. J. Biol. Chem. 278:40923-40932.
41. Mancini, F., Rigacci, S., Berti, A., Balduini, C., and Torti, M. 2007. The low-molecular-weight phosphotyrosine phosphatase is a negative regulator of FcγRIIA-mediated cell activation. Blood. 110:1871-1878.
42. Ibarrola, I., et al. 1997. Influence of tyrosine phosphorylation on protein interaction with FcγRIIa. Biochim. Biophys. Acta. 1357:348-358.
43. Chacko, G.W., Brandt, J.T., Coggeshall, K.M., and Anderson, C.L. 1996. Phosphoinositide 3-kinase and p72syk noncovalently associate with the low affinity Fcγ receptor on human platelets through an immunoreceptor tyrosine-based activation motif. J. Biol. Chem. 271:10775-10781.
44. Vossebeld, P.J., et al. 1997. Tyrosine phosphorylation-dependent activation of phosphatidylinositide 3-kinase occurs upstream of Ca2+-signalling induced by Fcγ receptor cross-linking in human neutrophils. Biochem. J. 323:87-94.
45. Gratacap, M.P., et al. 1998. Phosphatidylinositol 3,4,5-trisphosphate- dependent stimulation of phospholipase C-γ2 is an early key event in FcγRIIAmediated activation of human platelets. J. Biol. Chem. 273:24314-24321.
46. Oda, A., et al. 2000. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood. 95:1663-1670.
47. Thai, L.M., et al. 2003. Physical proximity and functional interplay of PECAM-1 with the Fc receptor FcγRIIa on the platelet plasma membrane. Blood. 102:3637-3645.
48. Pedicord, D.L., et al. 2003. CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists. Thromb. Haemost. 89:513-521.
49. Obergfell, A., et al. 2002. Coordinate interactions of Csk, Src, and Syk kinases with αIIbβ3 initiate integrin signaling to the cytoskeleton. J. Cell Biol. 157:265-275.
50. Arias-Salgado, E.G., et al. 2003. Src kinase activation by direct interaction with the integrin β cytoplasmic domain. Proc. Natl. Acad. Sci. U. S. A. 100:13298-13302.
51. Arias-Salgado, E.G., Lizano, S., Shattil, S.J., and Ginsberg, M.H. 2005. Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain. J. Biol. Chem. 280:29699-29707.
52. Reddy, K.B., Smith, D.M., and Plow, E.F. 2008. Analysis of Fyn function in hemostasis and αIIbβ3-integrin signaling. J. Cell Sci. 121:1641-1648.
53. Wang, R., Shattil, S.J., Ambruso, D.R., and Newman, P.J. 1997. Truncation of the cytoplasmic domain of β3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin αIIbβ3 complex. J. Clin. Invest. 100:2393-2403.
54. Dunkley, S., Lindeman, R., Evans, S., Casten, R., and Jepson, N. 2003. Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble. J. Thromb. Haemost. 1:2248-2250.
55. Dunkley, S., Evans, S., Gaudry, L., and Jepson, N. 2005. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Platelets. 16:462-468.
56. Morel, O., Jesel, L., Chauvin, M., Freyssinet, J.M., and Toti, F. 2003. Eptifibatide-induced thrombocytopenia and circulating procoagulant plateletderived microparticles in a patient with acute coronary syndrome. J. Thromb. Haemost. 1:2685-2687.
57. Boucheix, C., et al. 1983. Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemia antigen p 24). Inhibition of aggregation by ALB6Fab. FEBS Lett. 161:289-295.
58. Modderman, P.W., Huisman, H.G., van Mourik, J.A., and von dem Borne, A.E. 1988. A monoclonal antibody to the human platelet glycoprotein IIb/ IIIa complex induces platelet activation. Thromb. Haemost. 60:68-74.
59. Ockenhouse, C.F., Magowan, C., and Chulay, J.D. 1989. Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. J. Clin. Invest. 84:468-475.
60. Rubinstein, E., Boucheix, C., Urso, I., and Carroll, R.C. 1991. Fc gamma receptor-mediated interplatelet activation by a monoclonal antibody against beta 2 microglobulin. J. Immunol. 147:3040-3046.
61. Rubinstein, E., Urso, I., Boucheix, C., and Carroll, R.C. 1992. Platelet activation by cross-linking HLA class I molecules and Fc receptor. Blood. 79:2901-2908.
62. Kornecki, E., Walkowiak, B., Naik, U.P., and Ehrlich, Y.H. 1990. Activation of human platelets by a stimulatory monoclonal antibody. J. Biol. Chem. 265:10042-10048.
63. Gould, W.R., et al. 2005. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J. Thromb. Haemost. 3:733-741.
64. Brandt, J.T., Julius, C.J., Osborne, J.M., and Anderson, C.L. 1996. The mechanism of platelet aggregation induced by HLA-related antibodies. Thromb. Haemost. 76:774-779.
65. Schultz, D.R., et al. 1998. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br. J. Haematol. 103:849-857.
66. Schallmoser, K., et al. 2006. Specificities of platelet autoantibodies and platelet activation in lupus anticoagulant patients: a relation to their history of thromboembolic disease. Lupus. 15:507-514.
67. Rubinstein, E., Kouns, W.C., Jennings, L.K., Boucheix, C., and Carroll, R.C. 1991. Interaction of two GPIIb/IIIa monoclonal antibodies with platelet Fc receptor (Fc gamma RII). Br. J. Haematol. 78:80-86.
68. Berndt, M.C., et al. 1993. Topographical association of the platelet Fc-receptor with the glycoprotein IIb-IIIa complex. Platelets. 4:190-196.
69. Newman, P.J., Allen, R.W., Kahn, R.A., and Kunicki, T.J. 1985. Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody, AP-3. Blood. 65:227-232.
70. Wagner, C.L., et al. 1996. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 88:907-914.
71. McGregor, L., et al. 1989. Aggregation to thrombin and collagen of platelets from a Glanzmann thrombasthenic patient lacking glycoproteins IIb and IIIa. Thromb. Haemost. 62:962-967.
72. Newman, P.J., McEver, R.P., Doers, M.P., and Kunicki, T.J. 1987. Synergistic action of two murine monoclonal antibodies that inhibit ADP-induced platelet aggregation without blocking fibrinogen binding. Blood. 69:668-676.
73. Rosenfeld, S.I., et al. 1987. Human Fc gamma receptors: stable inter-donor variation in quantitative expression on platelets correlates with functional responses. J. Immunol. 138:2869-2873.
74. Tomiyama, Y., Kunicki, T.J., Zipf, T.F., Ford, S.B., and Aster, R.H. 1992. Response of human platelets to activating monoclonal antibodies: importance of FcγRII (CD32) phenotype and level of expression. Blood. 80:2261-2268.
75. Calverley, D.C., et al. 2003. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br. J. Haematol. 121:139-142.
76. Serrano, F.A., et al. 2007. Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease. Thromb. J. 5:7.
77. Chen, J., et al. 2003. Platelet FcγRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. J. Thromb. Haemost. 1:355-362.
78. Morton, L.F., et al. 1995. Integrin α2β1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple helical) and quaternary (polymeric) structures are sufficient alone for α2β1-independent platelet reactivity. Biochem. J. 306:337-344.
79. Pidard, D., Montgomery, R.R., Bennett, J.S., and Kunicki, T.J. 1983. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J. Biol. Chem. 258:12582-12586.
80. Looney, R.J., Abraham, G.N., and Anderson, C.L. 1986. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol. 136:1641-1647.
81. Faraday, N., Goldschmidt-Clermont, P., Dise, K., and Bray, P.F. 1994. Quantitation of soluble fibrinogen binding to platelets by fluorescence- activated flow cytometry. J. Lab. Clin. Med. 123:728-740.
82. Boylan, B., et al. 2008. Identification of Fc?RIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets. Blood. 112:2780-2786.